Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-H5-sfMR vaccine
- Development stage
- Unknown
- Lead developer
- Erasmus MC
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-H5-sfMR is an investigational recombinant viral vector vaccine developed by Erasmus MC (Universitair Medisch Centrum Rotterdam) in collaboration with the Ludwig Maximilian University of Munich for the prevention of highly pathogenic avian influenza A(H5N1). The vaccine utilizes a replication-deficient Modified Vaccinia virus Ankara (MVA) vector platform, grown in serum-free Munich-Rotterdam (sfMR) conditions, to deliver and express the hemagglutinin (HA) antigen of the influenza A/Vietnam/1194/2004 (H5N1, clade 1) virus. In clinical trials, MVA-H5-sfMR has been shown to be well tolerated and immunogenic, inducing robust neutralizing antibody responses against homologous and heterologous H5N1 strains, as well as cross-reactive T-cell responses, making it a promising candidate for pandemic influenza preparedness.
- Other names
- MVA-H5-sfMR vaccineMVA-H-5-sfMR vaccineMVA-H 5-sfMR vaccineMVA-H5MVA-H-5MVA-H 5
02
Targets
HA (Influenza A virus H5N1 hemagglutinin (A/Vietnam/1194/2004))
Beyond the preview
Go deeper on MVA-H5-sfMR vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-H5-sfMR vaccine.